Dynatronics Stock Price, News & Analysis
Company Description
Dynatronics Corporation (DYNT) is a medical device company that designs, manufactures, and sells restorative products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. According to company disclosures, Dynatronics focuses on high-quality restorative products designed to help patients achieve optimal health, serving a range of clinical and athletic care settings.
The company is incorporated in Utah and has its principal executive offices in Eagan, Minnesota, as reflected in its SEC filings. Dynatronics’ common stock trades under the symbol DYNT. Following a transition from The Nasdaq Stock Market, the company’s common stock has been quoted on the OTCQB Venture Market, as noted in its public communications. SEC filings identify its trading symbol as DYNT on OTCQB.
Business focus and product categories
Dynatronics describes itself as a medical device company committed to providing restorative products for clinical professionals. The company reports that it designs, manufactures, and sells a broad range of products used in:
- Physical therapy
- Rehabilitation
- Orthopedics
- Pain management
- Athletic training
Through its distribution channels, Dynatronics markets and sells products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and, in some disclosures, consumers. The company emphasizes that its offerings are used in clinical environments and athletic training centers.
Dynatronics’ products are marketed under a portfolio of brands that the company characterizes as high-quality and well-known within its industry. Across multiple press releases, Dynatronics lists brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™. In some releases, the company highlights these as legacy or established brands in rehabilitation and athletic training markets.
Customers and distribution
Company disclosures state that Dynatronics sells through distribution channels that reach a range of professional end users. These include:
- Orthopedists
- Physical therapists
- Chiropractors
- Athletic trainers
- Sports medicine practitioners
- Clinics and hospitals
In certain releases, Dynatronics also notes that it markets products to consumers, indicating that some of its restorative or therapeutic products may be accessible outside institutional clinical settings. The company positions its portfolio as supporting both rehabilitation and athletic training environments.
Brand portfolio and product positioning
Dynatronics’ public communications consistently emphasize its brand portfolio as a key element of its identity. The company states that its products are marketed under brands such as Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. In its financial results releases, Dynatronics describes these brands as high-quality and well-known in their respective segments, particularly in rehabilitation and athletic training.
In commentary around product development, Dynatronics has highlighted new additions to its rehabilitation furniture line, including Timber, Titan Premier, and Forged lines, which the company associates with treatment furniture and athletic training center products. These references underscore an ongoing focus on rehabilitation furniture and treatment tables within its broader restorative product mix.
Corporate developments and trading status
Dynatronics has disclosed changes in its trading venue and significant corporate events through SEC filings and press releases. In a June 2024 release, the company reported that it received written notice from Nasdaq that its common stock would be suspended from trading on Nasdaq due to failure to regain compliance with Nasdaq’s minimum bid price requirement. The company stated that it determined transitioning to the OTC Markets Group’s OTCQB Venture Market was the best course of action, and that OTCQB had approved quotation of its common stock. The company also indicated that its ticker symbol and CUSIP were not expected to change in connection with this transition and that it would remain a reporting company under the Securities Exchange Act of 1934.
Subsequent SEC filings provide further information about the company’s status. An 8-K dated January 12, 2026 reports that on January 9, 2026, Dynatronics Corporation and its wholly-owned subsidiaries filed voluntary petitions for relief under Chapter 7 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Minnesota. The filing states that the Debtors ceased operations and that a Chapter 7 trustee will be appointed to administer and liquidate the assets of each Debtor in accordance with the Bankruptcy Code. The same filing notes that, upon the appointment of the Chapter 7 trustee or trustees, the authority and powers of the company’s Board of Directors and executive officers to act on behalf of the Debtors would effectively be eliminated, and that the company’s directors and executive officers resigned or ceased to serve in those roles.
As a result of these Chapter 7 bankruptcy cases, Dynatronics is described in the 8-K as having ceased operations, with its assets subject to liquidation under the supervision of a Chapter 7 trustee. While the common stock remains identified in SEC filings as trading under the symbol DYNT on OTCQB, the company’s own disclosure indicates that it is in liquidation proceedings under Chapter 7.
Regulatory reporting and governance
Dynatronics has historically filed periodic reports and proxy statements with the SEC under the Securities Exchange Act of 1934. A definitive proxy statement (DEF 14A) dated October 28, 2025 describes the company’s annual meeting of shareholders held on December 11, 2025, including proposals to elect directors, ratify the appointment of an independent registered public accounting firm, and approve executive compensation on an advisory basis. An 8-K dated December 17, 2025 summarizes the voting results from that annual meeting, including director elections and advisory votes.
The company has also filed notifications of late filing (Form 12b-25) when it anticipated delays in submitting periodic reports, such as a notification regarding its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. In that filing, Dynatronics cited an unforeseen processing issue during the final stages of preparing financial statements and related disclosures, and indicated that it expected to file the report within the extension period provided under SEC rules.
Investment and research considerations
For investors and researchers, Dynatronics represents a medical device issuer whose business centered on restorative products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training, marketed under multiple established brands. However, the company’s January 2026 8-K filing makes clear that it has ceased operations and entered Chapter 7 bankruptcy, with a trustee responsible for liquidating its assets. Any assessment of DYNT as a security must therefore take into account the company’s disclosed bankruptcy status, the cessation of operations, and the implications of Chapter 7 liquidation for equity holders.